Back to News
Market Impact: 0.2
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
Source: GlobeNewswire
Healthcare & BiotechCorporate Guidance & Outlook
The RECEPTIVE-HS1 Phase 2 trial in moderate-to-severe hidradenitis suppurativa is expected to begin in 2026, with 16-week treatment-period data anticipated in the first half of 2028. The update establishes a long clinical-development timeline but provides no efficacy, safety, or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- Europe’s winter energy crunch may already be underway. Two U.S. stocks that may benefit
- Broadcom to lend Anthropic up to $42 billion to lease its chips, filing says
- Nike Warns Sales Slump Will Worsen This Fiscal Year
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Google unveils latest AI model, but Wall Street wants a breakout personal agent
- Accenture rallies more than 20% after earnings beat, heads for best day ever